
Imagion Biosystems Inc (AKA: Senior Scientific Inc) Profile last edited on: 5/7/2019
CAGE: 3YDX8
UEI:
Business Identifier: Nanotechnology-based cancer diagnostics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
11109 Country Club Drive NE
Albuquerque, NM 87111
Albuquerque, NM 87111
(505) 294-1298 |
N/A |
N/A |
Location: Single
Congr. District: 01
County: Bernalillo
Congr. District: 01
County: Bernalillo
Public Profile
In June 2011, Senior Scientific Inc was acquired by Manhatten Scientific (OTCQB:MHTX) - a firm focused on technology transfer and commercialization of transformative technologies in the nano medicine space withfacilites in New Mexico, New York and Montreal. Having expertise in nanotechnology and the physics of magnetic fields, along with the medical application of these fields, Senior Scientific focused on the rapidly emerging field of nanobiotechnology, with an emphasis on the early detection and localization of cancer and other human diseases. The firms technologies also held promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention. This technology, called Nanomagnetic relaxometry, relies upon the ability to detect tiny magnetic particles through the measurement of the magnetic fields they release after they are magnetized. Using specialized superparamagnetic nanoparticles with biocompatible coatings linked to specific antibodies, the firm is able to determine whether these particles are bound to their specific targets using the large difference between the relaxation times of bound and unbound particles. Because low frequency magnetic fields travel freely through human and animal tissue, Senior Scientific is able to measure these events both inside the body (in-vivo) and in tissue samples (ex-vivo). Preclinical research projects using this technique have focused on the early detection of breast cancer, ovarian cancer, leukemia, and Alzheimer's disease and non-invasive detection of transplant rejection. In 2016, it was announced that as the cancer diagnostic unit of Manhatten Scientific, Senior Scientifc would initsown right pursue an IPO and listing on the Australian Stock Exchange (ASX) and also changed the Senior Scientifc's name to Imagion Biosystems Inc.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2011 | 2 | NIH | $1,586,982 | |
Project Title: Improving Biopsies using Magnetic Nanoparticles | ||||
2010 | 2 | NIH | $921,801 | |
Project Title: Fast-Track:Biomagnetic In-Vivo Imaging Of Ovarian Cancer | ||||
2008 | 2 | NIH | $1,022,005 | |
Project Title: Biomagnetic Determinantion of Transplant Rejection | ||||
2008 | 2 | NIH | $1,935,748 | |
Project Title: A Biomagnetic Sensor for Detecting Breast Cancer | ||||
2007 | 1 | NIH | $141,319 | |
Project Title: Diagnosing Alzheimers Disease with Magnetic Nanoparticles |
Key People / Management
Gerald Grafe -- President
Spencer Falk -- Vice President, Marketing
Edward R Flynn -- Chief Scientific Officer
Manny Tsoupanarias -- Chief Executive Officer
Spencer Falk -- Vice President, Marketing
Edward R Flynn -- Chief Scientific Officer
Manny Tsoupanarias -- Chief Executive Officer